Federman & Sherwood Investigates Advaxis, Inc.
For Possible Violations of Federal Securities Laws
Oklahoma City, OK (January 22, 2015) – The law firm of Federman & Sherwood has initiated an investigation into Advaxis, Inc. [NASDAQ: ADXS] with respect to possible violations of federal securities laws.
Advaxis, Inc. (“Advaxis”) is a clinical stage biotechnology company focused on the development of cancer therapies. Federman & Sherwood is investigating whether Advaxis and certain of its officers and/or directors have violated the Securities Exchange Act of 1934.
SeekingAlpha published on January 21, 2015 an article which alleged that in a recent corporate presentation, Advaxis made misrepresentation. More specifically, they misrepresented the tumor response data for its ADXS-HPV compound, overstating its effectiveness in shrinking tumors. The article further alleges that Advaxis misled investors regarding the design of the planned Phase 3 trial. On this news, the shares of Advaxis fell $3.39 per share to close at $8.37 per share.
If you currently own common stock in Advaxis, Inc., have any information to assist in our investigation, have questions or concerns regarding this notice or your rights or interests in this matter, please click here to download and complete our Certification of Investment or you may contact William B. Federman with any questions you have regarding this investigation. Federman & Sherwood has extensive nationwide experience in representing investors in securities, derivative and merger-related shareholder class actions, and has been appointed as lead counsel in multiple complex cases across the country.
Posted on Thu, January 22, 2015
by Robin Hester filed under